Today’s clinical trials are faced with challenges such as high patient dropout rates, rising cost of drug development, significant failure rates, and an increase in trial duration. While the drug pipeline has grown over the last few years, the efficiencies in clinical trials have not followed a similar trend. Rather, it would be surprising to find that the clinical trials are still as inefficient as they were a decade ago, despite the introduction of technologies such as analytics. There is, therefore, a need to transform clinical trials for the better, by bringing in technological interventions to improve efficiency, speed, costs, and also make the trials more patient centric.

In order to transform their clinical trials, enterprises will need to prioritize their investments in these technologies, develop a strategy for external collaboration, and adopt a platform strategy to unify the clinical trial applications landscape.

Scope of the analysis

• Geography: Global
• Industry: Life sciences

Sources leveraged

• Expert analyst inputs
• Previous Everest Group research
• Secondary data sources that are publicly available

Contents

This report presents the current state of clinical trials, the factors responsible for the change in the trial ecosystem, six interventions that will change the face of clinical trials for the better, and the business imperatives for industry stakeholders to reach the desired state faster.

This report is structured across three key sections, each containing insights into the clinical trials ecosystem:

• Current state of clinical trials
• Future of clinical trials
• Drivers for change in the clinical trial landscape
• Key interventions that will change the trial landscape
• Patient-centric virtual trials
• Digital biomarkers and digital endpoints
• Using innovation to access untapped markets
• In silico clinical trials
• Adaptive trials
• Blockchain for clinical trial data management
• Business imperatives
• Developing a collaborative strategy
• Adopting a unified platform strategy for clinical trial management
• Prioritizing investments in promising technologies

Membership(s)

Life Sciences IT Services (ITS)